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Abstract
Background: Individuals with substance use disorders typically exhibit a predilection toward instant gratification with 
apparent disregard for the future consequences of their actions. Indirect evidence suggests that low dopamine D2-type 
receptor availability in the striatum contributes to the propensity of these individuals to sacrifice long-term goals for short-
term gain; however, this possibility has not been tested directly. We investigated whether striatal D2/D3 receptor availability 
is negatively correlated with the preference for smaller, more immediate rewards over larger, delayed alternatives among 
research participants who met DSM-IV criteria for methamphetamine (MA) dependence.
Methods: Fifty-four adults (n = 27 each: MA-dependent, non-user controls) completed the Kirby Monetary Choice Questionnaire, 
and underwent positron emission tomography scanning with [18F]fallypride.
Results: MA users displayed steeper temporal discounting (p = 0.030) and lower striatal D2/D3 receptor availability (p < 0.0005) 
than controls. Discount rate was negatively correlated with striatal D2/D3 receptor availability, with the relationship reaching 
statistical significance in the combined sample (r = -0.291, p = 0.016) and among MA users alone (r = -0.342, p = 0.041), but not 
among controls alone (r = -0.179, p = 0.185); the slopes did not differ significantly between MA users and controls (p = 0.5).
Conclusions: These results provide the first direct evidence of a link between deficient D2/D3 receptor availability and steep 
temporal discounting. This finding fits with reports that low striatal D2/D3 receptor availability is associated with a higher risk 
of relapse among stimulant users, and may help to explain why some individuals choose to continue using drugs despite 
knowledge of their eventual negative consequences. Future research directions and therapeutic implications are discussed.
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Introduction
Drug addiction is characterized by persistent drug use despite 
adverse consequences, perhaps in part because the instant 
pleasure garnered by using drugs is perceived to outweigh the 
long-term benefits of sobriety. Consistent with this idea, labora-
tory studies routinely find that individuals with substance use 
disorders display greater preference for smaller, more immedi-
ately available rewards (e.g. money, drugs) over larger, delayed 
alternatives than healthy controls (MacKillop et  al., 2011). 
Moreover, research indicates that those who most strongly 
favor the immediate options on such laboratory-based choice 
tasks are also most likely to relapse during attempted absti-
nence (Krishnan-Sarin et al., 2007; Yoon et al., 2007; MacKillop 
and Kahler, 2009; Mueller et al., 2009; Washio et al., 2011; Sheffer 
et al., 2012; Stanger et al., 2012 and also see Passetti et al., 2008; 
Landes et al., 2012). Nonetheless, few studies have attempted to 
elucidate the neural mechanisms underlying addicts’ inordinate 
preference for immediate rewards.
Dopamine is heavily implicated in intertemporal choice 
(for a review, see Winstanley, 2011), and indirect evidence sug-
gests that deficient dopamine D2/D3-type receptor-mediated 
dopaminergic neurotransmission in the striatum may be an 
important contributing factor to this immediacy bias. Like steep 
temporal discounting, low striatal D2/D3 receptor availability is 
observed among individuals with substance use disorders (for 
a review, see Trifilieff and Martinez, 2014), and has been linked 
with an increased likelihood of relapse (Martinez et  al., 2011; 
Wang et  al., 2012). Chronic exposure to methamphetamine 
(MA) or cocaine induces persistent reductions in striatal D2/D3 
receptor availability in rats (McCabe et al., 1987; Puig et al., 2014) 
and monkeys (Nader et al., 2006; Groman et al., 2012), and rats 
treated chronically with either of these drugs exhibit greater 
temporal discounting than controls (Richards et al., 1999; Paine 
et  al., 2003; Roesch et  al., 2007; Mendez et  al., 2010). Humans 
with attention-deficit hyperactivity disorder or obesity—two 
other disorders that are associated with low striatal D2/D3 recep-
tor availability (for a review, see Trifilieff and Martinez, 2014)—
also display greater temporal discounting than healthy controls 
(for a review, see Bickel et al., 2012). Greater temporal discount-
ing has also been observed among carriers of the A1 allele of the 
ANKK1 Taq1A polymorphism (Eisenberg et al., 2007), a genetic 
variant associated with low striatal D2 receptor density/binding 
in humans relative to A2 homozygotes (Jonsson et al., 1999).
Although an association between low striatal D2/D3 receptor 
availability and steep temporal discounting has been implied, 
this link has not been directly evaluated. We therefore examined 
striatal D2/D3 receptor availability in relation to temporal dis-
counting in research participants who met DSM-IV criteria for 
MA dependence and a group of healthy controls. MA-dependent 
individuals were selected as a group for study because case-con-
trol studies find that they display deficits in striatal D2/D3 recep-
tor availability (Volkow et al., 2001; Lee et al., 2009; Wang et al., 
2012) and exaggerated temporal discounting (Hoffman et  al., 
2006; Monterosso et al., 2007). We hypothesized that striatal D2/
D3 receptor availability would be negatively correlated with dis-
count rates among MA users, and possibly also among controls. 
Because tobacco use has also been linked with low striatal D2/D3 
receptor availability (among males; Fehr et al., 2008; Brown et al., 
2012) and steep temporal discounting (MacKillop et al., 2011), the 
association was explored as well in the control-group smokers. 
Because chronic MA abusers also display lower D2/D3 receptor 
availability than non-users in extrastriatal brain areas (London 
laboratory unpublished data), including several that have been 
implicated in intertemporal choice (for reviews, see Carter et al., 
2010; Wesley and Bickel, 2014), exploratory analyses were per-
formed to investigate whether extrastriatal D2/D3 receptor avail-
ability might also be negatively correlated with discount rate.
Methods
Participants
Procedures were approved by the University of California Los 
Angeles (UCLA) Office for Protection of Research Subjects. 
Participants were recruited using the Internet and local news-
paper advertisements. All provided written informed consent 
and underwent eligibility screening using questionnaires, the 
Structured Clinical Interview for DSM-IV (First et al., 1996), and a 
physical examination. Twenty-seven individuals who met criteria 
for current MA dependence but were not seeking treatment for 
their addiction and 27 controls completed the study. D2/D3 recep-
tor availability data from approximately half of the MA users 
and controls have been reported previously (Lee et al., 2009), and 
smaller subsets were included in other studies from our labo-
ratory regarding D2/D3 receptor availability (Brown et  al., 2012; 
Ghahremani et al., 2012; Zorick et al., 2012; Kohno et al., 2015).
The exclusion criteria were: central nervous system, cardiovas-
cular, pulmonary, hepatic, or systemic disease; HIV seropositive sta-
tus; pregnancy; lack of English fluency; MRI ineligibility (e.g. metal 
implants, claustrophobia); current use of psychotropic medica-
tions; current Axis I disorder including substance abuse or depend-
ence for any substance other than nicotine (or MA or cannabis for 
MA users only; all MA users met criteria for MA dependence, and 
2 met criteria for cannabis dependence; substance-induced mood 
disorders were also not exclusionary for this group).
A diagnosis of MA dependence and a positive urine test for 
MA at intake were required for MA-group participants, who 
completed the study as inpatients at the UCLA General Clinical 
Research Center, and were prohibited from using any drugs 
(besides nicotine in cigarettes) for 4–7 days before testing. MA 
users completed the behavioral and imaging measures 2 days 
apart on average (standard deviation [SD]  =  2.1; range: 1–11). 
Controls were studied on a nonresidential basis and completed 
the measures 22 days apart on average (SD = 28.0; range 1–111). 
All participants were required to provide a urine sample on each 
test day that was negative for amphetamine, cocaine, MA, ben-
zodiazepines, opioids, and cannabis. Compensation was pro-
vided in the form of cash, gift certificates, and vouchers.
Delay Discounting
Delay discounting was assessed with the Monetary-Choice 
Questionnaire (MCQ; Kirby et al., 1999), which presents partici-
pants with 27 hypothetical choices between a smaller, immedi-
ate monetary amount and a larger, delayed alternative. Most of 
the participants completed the task using a paper-and-pencil 
format, but some completed the task on a computer (10 controls 
[9 smokers], 4 MA users); the questions were presented in the 
same sequence, regardless of task format.
A logistic regression was performed on the data from each 
participant, separately, using his/her responses to all 27 choices 
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(coded as 0 for immediate-option and 1 for delayed-option 
selections) as the dependent variable, and the natural log of the 
equivalence k value associated with each test question as the 
independent variable. This k-equivalence value was the number 
that would equalize the immediate option with the delayed alter-
native, assuming the hyperbolic discounting function: V = A/(1 + 
kD), where V represents the perceived value of amount A made 
available D days in the future (Bickel et al., 2012). The parameter 
estimates from the logistic regression were used to calculate the 
k-equivalence value at which the function intersected 0.5 (the 
stochastic indifference point). This derived k value character-
ized the individual’s discount rate (Kirby et al., 1999; see Wileyto 
et al., 2004). Because the MCQ only probes discounting between 
a minimum k-equivalence of 0.0002 and a maximum of 0.25, 
these values were designated as the minimum and maximum k 
values, respectively, that could be assigned.
D2/D3 Receptor Availability
Dopamine D2/D3 receptor availability was assessed using a 
Siemens EXACT HR+ positron emission tomography (PET) scan-
ner in 3D mode with [18F]fallypride as the radioligand (Mukherjee 
et al., 1995). Following a 7 min transmission scan acquired using 
a rotating 68Ge/68Ga rod source to measure and correct for atten-
uation, PET dynamic data acquisition was initiated with a bolus 
injection of [18F]fallypride (~5 mCi ± 5%, specific activity ≥ 1 Ci/
μmol). Emission data were acquired in two 80 min blocks, sepa-
rated by a 10–20 min break.
Raw PET data were corrected for decay, attenuation, and 
scatter, and then reconstructed using ordered-subsets expec-
tation-maximization (3 iterations; 16 subsets), using ECAT v7.2 
software (CTI PET Systems Inc.). Reconstructed data were com-
bined into 16 images (each representing an average of 10 min of 
dynamic data), and the images were motion-corrected using FSL 
McFLIRT (Jenkinson et al., 2002), and co-registered to the indi-
vidual’s structural MRI scan image using a six-parameter, rigid-
body transformation computed with the ART software package 
(Ardekani et al., 1995). Structural images were magnetization-
prepared, rapid-acquisition, gradient-echo scans acquired 
during a separate session using a Siemens Sonata 1.5T MRI 
scanner. All images were registered to MNI152 space using FSL 
FLIRT (Jenkinson and Smith, 2001). Volumes of interest (VOIs) 
were derived from the Harvard-Oxford atlases transformed into 
individual native space, or defined using FSL FIRST (Ardekani 
et  al., 1995). VOIs of the functional striatal subdivisions were 
created as described previously (Mawlawi et al., 2001).
Time-activity data within VOIs were imported into the PMOD 
3.2 kinetic modeling analysis program (PMOD Technologies 
Ltd.), and time-activity curves were fit using the simplified ref-
erence tissue model 2 (SRTM2; Wu and Carson, 2002). The cere-
bellum (excluding the vermis) was used as the reference region 
(Vandehey et al., 2010). The rate constant for transfer of the tracer 
from the reference region to plasma (k2′) was computed as the 
volume-weighted average of estimates from receptor-rich regions 
(caudate and putamen), calculated using the simplified reference 
tissue model (Lammertsma and Hume, 1996), as suggested by 
Ichise et al. (2008). Time-activity curves were re-fit using SRTM2 
(Wu and Carson, 2002), with the computed k2′ value applied to all 
brain regions. Regional binding potential referred to non-displace-
able binding, calculated as BPND = (R1(K2′ / K2a) − 1), where R1 = K1/K1′ 
is the ratio of tracer-delivery parameters for the tissue of inter-
est and reference tissue, and k2a is the effective rate parameter for 
transfer of tracer from the tissue of interest to the plasma (Mintun 
et al., 1984; Logan et al., 1996; Innis et al., 2007). Volume-weighted 
bilateral averages of all VOIs were used for analyses.
Statistical Analyses
Continuous variables were assessed for homogeneity of variance 
across groups using Levene’s tests. Demographic variables were 
examined for group differences using two-tailed  independent- 
samples t-tests, Mann-Whitney U-tests, or Fisher’s exact tests, 
as appropriate. Group differences in discount rate and BPND 
were tested using separate independent samples t-tests, and 
potential confounding variables were assessed as covariates. 
As expected, the distribution of discount rates was positively 
skewed. Because a natural log transform yielded a more nor-
mal distribution, ln(k) was used for analyses. The threshold for 
statistical significance was set at α = 0.05 for all analyses. One-
tailed p-values are reported for analyses where a specific direc-
tional effect was predicted (e.g. higher discount rate and lower 
BPND in MA users on average relative to non-users, negative rela-
tionships between BPND and discount rate).
Exploratory analyses were also carried out to investigate 
whether discount rate is negatively correlated with BPND in 
extrastriatal regions. These analyses were restricted to regions 
that exhibit appreciable [18F]fallypride BPND (arbitrarily defined 
as >0.5; see Table 2).
Results
Participant Characteristics
The groups included similar proportions of males and females 
(p  =  0.414), and did not differ in age (p  =  0.386); however, MA 
users averaged significantly fewer years of formal education 
than controls (p = 0.015; Table 1). The majority of participants in 
both groups were white (MA group: 23 white [6 Hispanic/Latino], 
2 Asian, 2 other; controls: 22 white [5 Hispanic/Latino], 1 black, 
2 Asian, 1 Native American, 1 other). Most of the MA users, but 
only approximately half of the controls, were smokers (p = 0.018); 
among the smokers, the proportions of males and females were 
similar across groups. On average, MA users reported using MA 
for 9.1 years, and on 21.4 of the 30 days before enrolling in the 
study, with 2.7 grams used in the preceding week.
Delay Discounting
MA users tended to discount delayed options more steeply than 
controls [ln(k) means ± standard error of the mean (SEM): MA 
users  =  -3.52 ± 0.25, controls  =  -4.08 ± 0.33; t52  =  1.34, p  =  0.094, 
Cohen’s d = 0.36]. Neither sex (p = 0.969), age (p = 0.215), smok-
ing status (i.e. current smoker; p  =  0.301), nor years of educa-
tion (p  =  0.536) independently predicted discount rate when 
controlling for group; however, task format (i.e. administration 
on paper or a computer) emerged as an extraneous predictor of 
discount rate (p = 0.027), with the computerized version associ-
ated with steeper discounting. After controlling for task format, 
the group difference in discounting reached statistical signifi-
cance (F1,51 = 3.70, p = 0.030, ηp
2 = 0.068); the group difference was 
nearly significant when the two MA users who met criteria for 
cannabis dependence were excluded from analyses (F1,49 = 2.81, 
p = 0.050, ηp
2 = 0.054). As expected, control-group tobacco smok-
ers tended to discount delayed options more steeply (-3.79 ± 0.46) 
than nonsmokers (-4.39 ± 0.48), but this difference was not sig-
nificant when controlling for task format (p = 0.359, ηp
2 = 0.006). 
Discount rates did not differ substantially between either male 
(-3.59 ± 0.58) and female (-4.06 ± 0.66) smokers or non-smokers 
(males: -4.40 ± 0.70; females: -4.37 ± 0.88) in the control group or 
male (-3.65 ± 0.38) and female (-3.42 ± 0.34) MA users when con-
trolling for task format (all p > 0.36, ηp
2 < 0.01).
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Discount rate was not clearly related to years of regular MA 
use (r = 0.052, p = 0.796), days of MA use in the 30 days prior to 
study enrollment (r = -0.018, p = 0.928), or grams of MA used in 
the week prior to enrollment (r = -0.044, p = 0.830) among MA 
users, or to Fagerström Test for Nicotine Dependence (FTND; 
Heatherton et  al., 1991) scores (r  =  0.075, p  =  0.800), number 
of years smoking (r  =  0.043, p  =  0.884), or cigarettes per day 
(r = 0.325, p = 0.258) among control-group tobacco smokers.
Striatal D2/D3 Receptor Availability
BPND was significantly lower in the striata of MA users 
than controls (means ± SEM: MA users  =  17.13 ± 0.57, con-
trols  =  20.15 ± 0.70; t52  =  3.35, p  =  0.0005, Cohen’s d = 0.91). 
When controlling for participant group, striatal BPND was not 
independently predicted by years of education (p  =  0.208), 
but it was independently predicted by age (p  <  0.0005; BPND 
decreased as age increased), sex (p  =  0.010; lower among 
males), and smoking status (p = 0.012; lower among smokers). 
A  stepwise regression, controlling for group, indicated that 
age was the best predictor of striatal BPND, and neither sex nor 
smoking status significantly improved the predictivity of the 
model including group and age. The group difference in BPND 
remained significant after controlling for age (F1,51  =  21.37, 
p < 0.0005, ηp
2 = 0.295), and when the two MA users who met 
criteria for cannabis dependence were excluded from analy-
ses (F1,49 = 19.66, p < 0.0005, ηp
2 = 0.286). Although striatal BPND 
was slightly lower among control-group smokers (18.72 ± 1.07) 
than non-smokers (21.69 ± 0.70), this difference was not sig-
nificant when controlling for age (p = 0.276, ηp
2 = 0.015). Among 
controls, when controlling for age, striatal BPND was signifi-
cantly lower in male (16.55 ± 1.20) than female (21.62 ± 1.15) 
smokers (F1,11  =  9.70, p  =  0.005, ηp
2  =  0.469), but did not dif-
fer substantially between male (20.84 ± 1.02) and female 
(23.05 ± 0.36) nonsmokers (p  =  0.144, ηp
2  =  0.112). Striatal 
BPND was only marginally lower among male (16.52 ± 0.63) 
than female (17.62 ± 0.90) MA users when controlling for age 
(p = 0.478, ηp
2 < 0.0005).
Among MA users, striatal BPND was significantly negatively 
correlated with years of regular MA use (r =  -0.404, p = 0.036), 
but not with days of MA use in the 30 days prior to study enroll-
ment (r  =  -0.270, p  =  0.172) or grams of MA used in the week 
prior to enrollment (r =  -0.222, p = 0.266) when controlling for 
age. Among control-group tobacco smokers, striatal BPND tended 
to be negatively correlated with FTND score (r = -0.502, p = 0.068), 
but not with number of years smoking (r = -0.285, p = 0.322) or 
cigarettes per day (r = -0.286, p = 0.322) when controlling for age.
Relationship Between Delay Discounting and Striatal 
D2/D3 Receptor Availability
Combined Sample
A significant negative correlation between discount rate and 
striatal BPND was found when the data from both groups of par-
ticipants were combined (r = -0.291, p = 0.016), with BPND explain-
ing 8.5% of the variance in discount rates across the pooled 
sample. In post hoc analyses, negative relationships were seen 
in all three striatal subdivisions (limbic striatum [LST]: r = -0.217, 
p = 0.057; associative striatum [AST]: r = -0.298, p = 0.014; sen-
sorimotor striatum [SMST]: r  =  -0.258, p  =  0.030), but only the 
correlation in the AST remained significant following correction 
for multiple comparisons using the Holm-Bonferroni method. 
Similar results were obtained with age-adjusted BPND values 
(whole striatum: r = -0.251, p = 0.033; LST: r = -0.171, p = 0.108; 
AST: r = -0.259, p = 0.029; SMST: r = -0.212, p = 0.062; age-adjusted 
values were calculated by adding the residual values obtained 
by regressing BPND on age in the combined sample to the sam-
ple mean for each participant). Partial correlations indicated 
that controlling for task format and the number of days elapsed 
between measures did not substantially alter the relationships 
between discount rate and striatal BPND (unadjusted BPND values: 
rpartial = -0.223, p = 0.058; rpartial = -0.152, p = 0.144; rpartial = -0.223, 
p  =  0.058; rpartial  =  -0.189, p  =  0.092; age-adjusted BPND values: 
rpartial = -0.187, p = 0.095; rpartial = -0.106, p = 0.230; rpartial = -0.185, 
p = 0.097; rpartial =  -0.145, p = 0.155 for the whole striatum, LST, 
AST, and SMST, respectively); none of the partial correlation 
coefficients differed significantly from the respective bivariate 
coefficients (all p > 0.68).
Sobel tests indicated that striatal BPND did not mediate the 
group difference in discount rate, regardless of whether age-
adjusted BPND values were used, and this did not depend on task 
format (all p > 0.29). Analogous analyses yielded similar results 
in each of the three striatal functional subdivisions (all p > 0.23).
MA Users 
Discount rate was significantly negatively correlated with 
striatal BPND (r = -0.342, p = 0.041), which explained 12% of the 
variance in discount rate across MA users (Figure 1). Negative 
relationships were seen in all three striatal subdivisions (LST: 
r = -0.194, p = 0.166; AST: r = -0.322, p = 0.050; SMST: r = -0.330, 
p  =  0.046; Figure  2), but none reached significance after cor-
rection for multiple comparisons (Holm-Bonferroni method). 
Similar results were obtained with age-adjusted BPND values 
(whole striatum: r = -0.321, p = 0.052; LST: r = -0.153, p = 0.223; 
AST: r  =  -0.307, p  =  0.060; SMST: r  =  -0.324, p  =  0.049). Partial 
correlations indicated that controlling for task format and the 
number of days elapsed between measures did not substantially 
alter the relationships between discount rate and striatal BPND 
(unadjusted BPND values: rpartial = -0.333, p = 0.052; rpartial = -0.217, 
p = 0.149; rpartial = -0.305, p = 0.069; rpartial = -0.329, p = 0.054; age-
adjusted BPND values: rpartial  =  -0.276, p  =  0.091; rpartial  =  -0.152, 
p = 0.235; rpartial = -0.248, p = 0.116; rpartial = -0.281, p = 0.087 for the 
Table 1. Characteristics of Research Participants
Group Controls (n = 27) MA users (n = 27)
Sex (M/F) 16/11 12/15
Age (years) 35.4 ± 8.8 (19–51) 33.3 ± 9.3 (19–48)
Education (years) 14.2 ± 2.2 (8–18) 12.8 ± 1.9 (9–16)*
No. daily tobacco 8/6 11/12*
 smokers (M/F)
Cigarettes per day 12.9 ± 4.9 (8–20) 11.5 ± 9.6 (1–40)
 (daily smokers only)
Years smoking 19.1 ± 11.4 (3–36) 17.4 ± 9.8 (2–35)
 (daily smokers only)
FTND score 3.5 ± 2.1 (0–8) 2.7 ± 2.4 (0–9)
 (daily smokers only)
Duration of regular MA N/A 9.1 ± 6.8 (1.5–24)
use (years)
Frequency of MA use N/A 21.4 ± 7.1 (5–30)
 (days in last 30 days)
Intensity of MA use N/A 2.7 ± 2.7 (0.6–14.5)
 (grams in last week)
Data are presented as mean ± SD (range), except for sex and smoking status.
FTND: Fagerström Test for Nicotine Dependence
(possible range: 0 [low] - 10 [high]; Heatherton et al., 1991)
*Significant group difference, p < .05
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whole striatum, LST, AST, and SMST, respectively); none of the 
partial correlation coefficients differed significantly from the 
respective bivariate coefficients (all p > 0.82).
Controls 
Discount rate tended to be negatively correlated with striatal 
BPND among controls, but this relationship did not reach statisti-
cal significance in either the whole striatum (r = -0.179, p = 0.185; 
Figure  1) or any of the striatal subdivisions (LST: r  =  -0.158, 
p = 0.215; AST: r = -0.209, p = 0.147; SMST: r = -0.142, p = 0.240; 
Figure 2). Similar results were obtained with age-adjusted BPND 
values (whole striatum: r  =  -0.100, p  =  0.310; LST: r  =  -0.074, 
p = 0.356; AST: r = -0.130, p = 0.260; SMST: r = -0.050, p = 0.401). 
There was no indication that discount rate was more strongly 
correlated with striatal BPND in smokers than nonsmokers (data 
not shown). Partial correlations indicated that controlling for 
task format and the number of days elapsed between measures 
did not substantially alter the relationships between discount 
rate and striatal BPND (unadjusted BPND values: rpartial  =  -0.025, 
p = 0.453; rpartial = -0.014, p = 0.473; rpartial = -0.044, p = 0.418; rpar-
tial  =  -0.006, p  =  0.490; age-adjusted BPND values: rpartial  =  0.018, 
p  =  0.465; rpartial  =  0.028, p  =  0.447; rpartial  =  0.001, p  =  0.499; rpar-
tial = 0.040, p = 0.425 for the whole striatum, LST, AST, and SMST, 
respectively); none of the partial correlation coefficients dif-
fered significantly from the respective bivariate coefficients (all 
p > 0.56).
Tests comparing the slopes of the correlations revealed no 
significant group differences with respect to the whole striatum 
or any of the functional subdivisions (all p > 0.30).
Exploratory Analyses in Extrastriatal Regions
Negative relationships between discount rate and BPND were 
found in all of the extrastriatal regions of MA users (Table  2). 
Notably, among MA users, correlations at p < 0.05 were found in 
the midbrain, anterior cingulate cortex (ACC), and thalamus. In 
the combined sample, correlations at p < 0.05 were found in the 
amygdala, hippocampus, and ACC. No correlations at p  <  0.05 
were found in extrastriatal VOIs among controls. None of the 
correlations were significant following correction for multiple 
comparisons using the Holm-Bonferroni method.
Tests comparing the slopes of the correlations revealed a 
significant group difference with respect to the midbrain (unad-
justed BPND values: p = 0.076; age-adjusted BPND values: p = 0.041), 
but the slopes of the correlations between ln(k) and BPND were 
not significantly different between controls and MA users with 
Figure 1. Regression lines illustrate correlations between delay discounting [rep-
resented as the natural log of each individual’s discount rate; ln(k)] and striatal 
dopamine D2/D3 receptor availability (indexed by [
18F]fallypride non-displaceable 
binding potential [BPND], unadjusted) in whole striata of methamphetamine (MA) 
users and non-user controls. Pearson product-moment correlation coefficients 
are shown (r values).
Figure 2. Regression lines illustrate correlations between delay discounting [represented as the natural log of each individual’s discount rate; ln(k)] and striatal dopa-
mine D2/D3 receptor availability (indexed by [
18F]fallypride non-displaceable binding potential [BPND], unadjusted) in the striatal functional subdivisions of metham-
phetamine (MA) users and non-user controls. Pearson product-moment correlation coefficients are shown (r values).
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respect to any of the other brain regions examined in explora-
tory analyses (all other p > 0.19).
Discussion
In line with previous reports, MA users displayed lower striatal 
D2/D3 receptor availability (Volkow et al., 2001; Lee et al., 2009; 
Wang et al., 2012) and higher discount rates (Hoffman et al., 2006; 
Monterosso et al., 2007) than controls, on average. As hypothe-
sized, discount rate was significantly negatively correlated with 
striatal D2/D3 receptor availability in the combined sample and 
among MA users alone. Although the slopes of the striatal cor-
relations were not significantly different between controls and 
MA users, the relationship did not reach statistical significance 
among controls alone. Exploratory analyses revealed negative 
relationships between discount rate and D2/D3 receptor avail-
ability in every extrastriatal region examined among MA users, 
but none retained significance following correction for multiple 
comparisons.
While substantial evidence implicates dopamine as a key 
determinant of intertemporal choice (for reviews, see Peters 
and Buchel, 2011; Winstanley, 2011), this study is the first to 
link temporal discounting directly with a measure of dopa-
mine signaling capacity. The findings indicate that deficient 
D2/D3 receptor availability may contribute to steep temporal 
discounting among individuals with substance use disorders, 
attention-deficit hyperactivity disorder, or obesity (for a review, 
see Bickel et al., 2012), and carriers of the A1 allele of the ANKK1 
Taq1A polymorphism (Eisenberg et  al., 2007). This reasoning 
is supported by reports that rats treated chronically with MA 
or cocaine display evidence of greater discounting of delayed 
rewards than saline-treated rats (Richards et  al., 1999; Paine 
et al., 2003; Roesch et al., 2007; Mendez et al., 2010), as both of 
both of these stimulants induce persistent reductions in striatal 
D2/D3 receptor availability in rats (McCabe et al., 1987; Puig et al., 
2014) and monkeys (Nader et al., 2006; Groman et al., 2012) fol-
lowing chronic exposure.
The results are also compatible with the literature concerning 
the neuroanatomical substrates of intertemporal choice. There 
was evidence of correlations involving several brain regions that 
have been implicated by functional neuroimaging and lesion 
studies as playing a role in selecting between immediate and 
delayed rewards: e.g. the midbrain, dorsal striatum, globus pal-
lidus, thalamus, amygdala, hippocampus, ACC, and insula (for 
reviews, see Peters and Buchel, 2011; Wesley and Bickel, 2014). 
The prefrontal cortex (PFC) is critically important for the ability 
to resist temptation for instant gratification in order to achieve 
long-term goals (Goldstein and Volkow, 2011), and striatal D2/D3 
receptor availability modulates PFC activity when goal-directed 
choices are made (Kohno et al., 2015). Moreover, D2/D3 receptor 
availability in the putamen has been shown to be negatively 
correlated with glucose metabolism in the orbitofrontal cor-
tex, which is implicated in delaying gratification (Goldstein and 
Volkow, 2011), especially among MA users (Volkow et al., 2001).
Choosing a smaller, more immediately available reward over 
a larger, more delayed alternative can be considered as an impul-
sive choice. However, while striatal D2/D3 receptor availability 
has been shown to be negatively correlated with trait impulsiv-
ity among MA users (i.e. total score on the Barratt Impulsiveness 
Scale v.11; BIS-11; Lee et al., 2009), there was no evidence that 
BIS-11 total scores were correlated with discount rates in this 
sample of participants (data not shown). Still, as expected, total 
BIS-11 scores were robustly higher among MA users than con-
trols on average in this sample, and were negatively correlated 
with striatal D2/D3 receptor availability when controlling for age 
in the combined sample (data not shown). This result implies 
that even though both trait impulsivity and temporal discount-
ing are related to striatal D2/D3 receptor availability, they repre-
sent at least partially separable constructs.
One limitation of this study is that [18F]fallypride has com-
parably high affinity for both D2 and D3 dopamine receptors 
(Elsinga et al., 2006; Banerjee and Prante, 2012), particularly as 
levels of D3 receptors may be higher than once estimated in mul-
tiple brain regions, including the striatum (Sun et al., 2012, 2013). 
Nevertheless, several lines of research suggest that individuals 
with substance use disorders, including MA users (Boileau et al., 
2012), have higher densities of D3 receptor levels in striatal and 
extrastriatal brain regions than those who do not frequently 
abuse drugs (Payer et  al., 2014). Thus, it seems probable that 
the lower [18F]fallypride BPND among MA users primarily reflects 
lower D2 receptor availability in this group compared to con-
trols. An additional limitation includes the possibility of com-
petition with endogenous dopamine influencing [18F]fallypride 
BPND (Cropley et al., 2008; Ceccarini et al., 2012). That IQ was not 
assessed is also a limitation, because IQ has been found to be 
significantly correlated with delay discounting (de Wit et  al., 
2007), and a group difference in the former could therefore over-
shadow the true group difference in the latter.
There are also some caveats that should be considered when 
interpreting the results of this study. First, the MCQ has limited 
ability to provide precise estimates of discount rates for indi-
viduals who discount very steeply. That is, the choice items 
only probe preference up to a maximum k-equivalence value of 
0.25, and this value was assigned as a conservative estimate of 
Table 2. Exploratory Correlational Analyses
 
Combined sample (N = 54) Controls (n = 27) MA users (n = 27)
Unadjusted BPND Age-adjusted BPND Unadjusted BPND Age-adjusted BPND Unadjusted BPND Age-adjusted BPND
Amygdala -0.302 (0.013) -0.264 (0.027) -0.279 (0.080) -0.205 (0.152) -0.275 (0.083) -0.251 (0.103)
Hippocampus -0.278 (0.021) -0.236 (0.043) -0.220 (0.135) -0.137 (0.248) -0.295 (0.068) -0.322 (0.051)
Globus pallidus -0.181 (0.096) -0.131 (0.173) -0.052 (0.398) 0.036 (0.570) -0.303 (0.062) -0.283 (0.076)
Thalamus -0.194 (0.080) -0.137 (0.161) -0.065 (0.374) 0.044 (0.586) -0.334 (0.045) -0.305 (0.061)
Midbrain -0.078 (0.287) -0.039 (0.388) 0.136 (0.750) 0.188 (0.826) -0.376 (0.027) -0.381 (0.025)
mOFC -0.210 (0.064) -0.149 (0.141) -0.235 (0.119) -0.098 (0.313) -0.168 (0.202) -0.133 (0.254)
ACC -0.270 (0.024) -0.228 (0.049) -0.217 (0.138) -0.099 (0.311) -0.368 (0.030) -0.372 (0.028)
Insula -0.164 (0.118) -0.086 (0.269) -0.093 (0.323) 0.072 (0.639) -0.288 (0.073) -0.314 (0.055) 
Data are presented as Pearson correlation coefficients (p value; one-tailed, uncorrected).
BPND age-adjustments made at the combined sample level.
mOFC: medial orbitofrontal cortex; ACC: anterior cingulate cortex 
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discount rate to individuals whose calculated k value was pre-
dicted to exceed this value (3 controls, 2 MA users). Second, BPND 
values were highly correlated across all VOIs examined in both 
groups of participants, which limits the ability to draw conclu-
sions regarding the relative importance of D2/D3 receptor avail-
ability in specific brain regions to discount rate. Finally, as there 
is some evidence that abstinence from drugs can increase tem-
poral discounting among addicted individuals (Field et al., 2006), 
it is possible that abstinence from MA may have amplified the 
difference in discount rate between MA users and controls.
The results of this study may help to explain why low stri-
atal D2/D3 receptor availability is associated with poor treatment 
response among individuals with MA dependence (Wang et al., 
2012) and cocaine dependence (Martinez et al., 2011). This view 
seems reasonable given that steep temporal discounting has 
also been linked with poor treatment response among cocaine-
dependent individuals (Washio et al., 2011), and predicts relapse 
among smokers (Krishnan-Sarin et al., 2007; Yoon et al., 2007; 
MacKillop and Kahler, 2009; Mueller et al., 2009; Sheffer et al., 
2012). The present results lend empirical support to a theoreti-
cal model in which Trifilieff and Martinez (2014) propose that, 
“low D2 receptor levels and dopamine transmission in the ven-
tral striatum lead to impulsive behavior, including the choice 
for smaller, immediate rewards over larger, but delayed or more 
effortful, rewards, which may represent an underlying behavio-
ral pattern in addiction.” Consistent with this model, we found 
evidence of a negative correlation between discount rate and D2/
D3 receptor availability in the limbic striatal subdivision (primar-
ily the ventral striatum). The correlation in the limbic striatum 
did not reach statistical significance, possibly due to the high 
D3/D2 receptor ratio in this region (Payer et al., 2014) and partial 
volume effects.
An important question for future research is to determine 
whether interventions that increase D2/D3 receptor availability 
can reduce temporal discounting, at least among those with low 
D2/D3 receptor availability. Pharmacological interventions could 
prove useful to this end. For example, varenicline increases stri-
atal D2/D3 receptor availability in rats (Crunelle et al., 2012), and 
in a study of human smokers, males (but not females) treated 
with varenicline showed lower temporal discounting than pla-
cebo-treated controls (Ashare and McKee, 2012). This finding is 
compelling considering that dorsal striatal D2/D3 receptor avail-
ability is lower in male (but not female) smokers compared to 
nonsmoker controls (Brown et al., 2012). There also is evidence 
that rimonabant increases striatal D2/D3 receptor availability 
(Crunelle et al., 2013), and can decrease discounting of delayed 
rewards in rats (Boomhower et  al., 2013, also see Pattij et  al., 
2007; Wiskerke et  al., 2011). Nonpharmacological approaches 
may be useful as well, as there is preliminary evidence that 
intensive exercise can increase striatal D2/D3 receptor avail-
ability in MA-dependent individuals (Robertson et al., 2013) and 
patients with early-stage Parkinson’s disease (Fisher et al., 2013). 
Similarly, in a mouse model of Parkinson’s disease, higher stri-
atal D2/D3 receptor availability and D2 receptor expression was 
noted among those exposed to high-intensity exercise relative 
to non-exercising controls (Vučcković et al., 2010).
Establishing a causal link between D2/D3 receptor availabil-
ity and temporal discounting is likely to have significant clinical 
implications. This is because there is evidence that interven-
tions that reduce temporal discounting are useful for treating 
disorders that are associated with both steep discounting and 
low striatal D2/D3 receptor availability. For instance, contingency 
management decreases discounting among cocaine-dependent 
individuals (Landes et  al., 2012) and smokers (Yi et  al., 2008), 
and methylphenidate decreases discounting in children with 
attention-deficit hyperactivity disorder (Shiels et al., 2009). More 
importantly, greater reductions in discounting predict a greater 
likelihood of protracted abstinence among cocaine users (Black 
and Rosen, 2011) and smokers (Secades-Villa et al., 2014). Thus, 
if a causative link between D2/D3 receptor availability and tem-
poral discounting is established, it may lead to the development 
of novel D2/D3-targeted interventions which could be used to 
more effectively treat a variety of disorders.
In conclusion, the results of this study indicate that low D2/
D3 receptor availability is associated with steep temporal dis-
counting. This link may explain why some individuals choose to 
continue using drugs despite knowledge of their future negative 
consequences, and could help to guide strategies for treating 
substance abuse and other psychiatric disorders.
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